一项评估 BIIB017(聚乙二醇干扰素 Beta-1a)在儿童参与者中用于治疗复发缓解型多发性硬化症的安全性、耐受性和有效性的研究
一项开放标签、随机、多中心、主动控制、平行组研究,以评估 BIIB017 在 10 岁至 18 岁以下儿童受试者中用于治疗复发缓解型多发性硬化症的安全性、耐受性和有效性,可选开放标签扩展
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part 1 of the study.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Levant
-
Jerusalem、Levant、以色列、9112001
- Hadassah University Hospital - Ein Kerem
-
-
Tel Aviv
-
Petach-Tikva、Tel Aviv、以色列、4920235
- Schneider Children's Medical Center
-
-
-
-
-
Belgorod、俄罗斯、308007
- RSBIH 'Belgorod Regional Clinical Hospital of Saint Ioasaf'
-
Moscow、俄罗斯、119602
- SBHI
-
Moscow、俄罗斯、129110
- SBIH of Moscow region "Moscow Regional Scientific & Research
-
Rostov-on-Don、俄罗斯、344022
- SBEI HPE 'Rostov State Medical University' of the MoH of the RF
-
Yaroslavl、俄罗斯、150000
- State Budgetary Institution of Healthcare of Yaroslavl region 'Clinical Hospital # 2'
-
-
Bashkortostan Republic
-
Ufa、Bashkortostan Republic、俄罗斯、450077
- SBEI HPE 'Bashkir State Medical University' of the MoH of the RF
-
-
Krasnoyarsk Krai
-
Krasnoyarsk、Krasnoyarsk Krai、俄罗斯、660037
- FSBI "Federal Siberian Scientific-Clinical Center of FMBA"
-
-
Oblast
-
Tomsk、Oblast、俄罗斯、634009
- Nebbiolo LLC
-
-
Sankt-Peterburg
-
Saint Petersburg、Sankt-Peterburg、俄罗斯、197110
- LLC National center for socially significan disease
-
-
Siberia
-
Kemerovo、Siberia、俄罗斯、650066
- SAIH 'Kemerovo Regional Clinical Hospital'
-
-
-
-
-
Sofia、保加利亚、1113
- MHATNP 'Sv.Naum', EAD
-
-
-
-
-
Zagreb、克罗地亚、10000
- University Hospital Centre Zagreb
-
Zagreb、克罗地亚、10000
- Children's Hospital Zagreb
-
Zagreb、克罗地亚、10000
- Clinical Hospital Center 'Sestre Milosrdnice'
-
-
Dalmatia
-
Split、Dalmatia、克罗地亚、21000
- University Hospital Centre Split
-
-
-
-
-
Budapest、匈牙利、1083
- Semmelweis Egyetem
-
-
Baranya
-
Pécs、Baranya、匈牙利、7623
- Pecsi Tudomanyegyetem KK
-
-
Hajdú-Bihar
-
Debrecen、Hajdú-Bihar、匈牙利、4032
- Debreceni Egyetem
-
-
-
-
-
Ankara、土耳其(türkiye)、06500
- Gazi University Medical Faculty Clinical Research Unit
-
Antalya、土耳其(türkiye)、07059
- Akdeniz University Medical Faculty
-
Izmir、土耳其(türkiye)、35210
- Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
-
Samsun、土耳其(türkiye)、55139
- Ondokuz Mayis Univ. Med. Fac.
-
-
-
-
Balkans
-
Belgrade、Balkans、塞尔维亚、11000
- Clinic of Neurology and Psychiatry for Children and Youth
-
Belgrade、Balkans、塞尔维亚、11000
- University Children Hospital
-
Belgrade、Balkans、塞尔维亚、11070
- Mother and Child Health Care Institute of Serbia ,,Dr Vukan Cupic''
-
-
-
-
-
Thessaloniki、希腊、54642
- General Hospital of Thessaloniki 'Hippokration'
-
-
Thessaly
-
Larissa、Thessaly、希腊、41110
- General Hospital of Larissa
-
-
-
-
-
Berlin、德国、13353
- Charité - Campus Virchow-Klinikum
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau、Baden-Wurttemberg、德国、79106
- Universitaetsklinikum Freiburg
-
-
Lower Saxony
-
Göttingen、Lower Saxony、德国、37075
- Universitaetsmedizin Goettingen
-
-
North Rhine-Westphalia
-
Bochum、North Rhine-Westphalia、德国、44791
- St. Josef-Hospital Universitaetsklinikum
-
-
-
-
-
Florence、意大利、50139
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Naples、意大利、80131
- Azienda Ospedaliera Universitaria 'Federico II'
-
Naples、意大利、80138
- Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli"
-
-
-
-
-
Hradec Králové、捷克语、50333
- Fakultni nemocnice Hradec Kralove
-
-
-
-
-
Bratislava、斯洛伐克、83340
- Narodny ustav detskych chorob
-
-
-
-
East Flanders
-
Ghent、East Flanders、比利时、9000
- Universitair Ziekenhuis Ghent
-
-
Wallonia
-
Liège、Wallonia、比利时、4000
- Clinique CHC MontLégia
-
-
-
-
-
Riyadh、沙特阿拉伯、11461
- King Saud University
-
-
Mecca Region
-
Jeddah、Mecca Region、沙特阿拉伯、40047
- King Faisal Specialist Hospital & Research Center
-
-
-
-
Bas Rhin
-
Strasbourg、Bas Rhin、法国、67098
- CHU Strasbourg - Hôpital Hautepierre
-
-
Haute Garonne
-
Toulouse、Haute Garonne、法国、31059
- Hopital Purpan
-
-
Herault
-
Montpellier、Herault、法国、34295
- Hopital Gui de Chauliac
-
-
Nord
-
Lille、Nord、法国、59037
- Hopital Roger Salengro - CHU Lille
-
-
Val De Marne
-
Le Kremlin-Bicêtre、Val De Marne、法国、94275
- Hôpital Bicêtre
-
-
-
-
Victoria
-
Parkville、Victoria、澳大利亚、3052
- Royal Children's Hospital
-
-
-
-
Shuwaikh
-
Ash Shuwaykh、Shuwaikh、科威特、12345
- Ibn Sina Hospital
-
-
-
-
-
Monastir、突尼斯、5000
- Hôpital Fattouma Bourghiba
-
Sfax、突尼斯、3029
- Hôpital Habib Bourguiba
-
-
Mannouba
-
Manouba、Mannouba、突尼斯、2010
- Hopital Razi
-
-
-
-
California
-
La Jolla、California、美国、92024
- UC San Diego Health
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27514
- UNC Hospitals
-
-
Virginia
-
Norfolk、Virginia、美国、23502
- Meridian Clinical Research
-
-
-
-
-
Coimbra、葡萄牙、3000-602
- Centro Hospitalar e Universitário de Coimbra E.P.E. - Hospital Pediátrico
-
Porto、葡萄牙、4099-001
- Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
-
-
Lisbon District
-
Lisbon、Lisbon District、葡萄牙、1649-035
- Centro Hospitalar e Universitário Lisboa Norte E.P.E.
-
Loures、Lisbon District、葡萄牙、2674-514
- Hospital Beatriz Ângelo
-
-
Minho
-
Braga、Minho、葡萄牙、4710-243
- Hospital de Braga
-
-
-
-
-
Córdoba、西班牙、14011
- Hospital Universitario Reina Sofia
-
Madrid、西班牙、28034
- Hospital Universitario Ramon y Cajal
-
-
Barcelona
-
Esplugues de Llobregat、Barcelona、西班牙、08950
- Hospital Sant Joan de Deu
-
-
Murcia
-
El Palmar、Murcia、西班牙、30120
- Hospital Universitario Virgen de la Arrixaca
-
-
-
-
Buenos Aires
-
Ciudad Autonoma Buenos Aires、Buenos Aires、阿根廷、1199
- Hospital Italiano de Buenos Aires
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
Part 1:
- Must have a diagnosis of RRMS as defined by the revised consensus definition for pediatric MS.
- Must have an EDSS score between 0.0 and 5.5.
- Must have experienced >= 1 relapse in the 12 months prior to randomization (Day 1) or >= 2 relapses in the 24 months prior to randomization (Day 1) or have evidence of asymptomatic disease activity (Gd-enhancing lesions) on brain MRI in the 6 months prior to randomization (Day 1).
Part 2:
• Participants who completed the study treatment in Part 1 (Week 96 Visit), as per protocol.
Key Exclusion Criteria:
Part 1:
- Primary progressive, secondary progressive, or progressive relapsing MS. These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Participants with these conditions may also have superimposed relapses but are distinguished from relapsing participants by the lack of clinically stable periods or clinical improvement.
- History of severe allergic or anaphylactic reactions or known drug hypersensitivity.
- Known allergy to any component of Avonex or BIIB017 formulation.
- Occurrence of an MS relapse that has occurred within 30 days prior to randomization (Day 1) and/or the participant has not stabilized from a previous relapse prior to randomization (Day 1).
- Any previous treatment with PEGylated human IFN β-1a.
Part 2:
- Any significant changes in medical history occurring after enrollment in Part 1, including laboratory test abnormalities or current clinically significant conditions that, in the opinion of the Investigator, would have excluded the participant's participation in Part 1. The Investigator must re-assess the participant's medical fitness for participation and consider any factors that would preclude treatment.
- The participant could not tolerate BIIB017 in Part 1.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:BIIB017 (peginterferon beta-1a)
Participants will receive subcutaneous (SC) injection of BIIB017 (peginterferon beta-1a) 63 microgram (μg) on Day 1, followed by 94 μg at Week 2, followed by 125 μg at Week 4, and then 125 μg SC injection every 2 weeks up to Week 96 in Part 1 of the study. Eligible participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks. |
Administered as specified in the treatment arm
其他名称:
|
|
有源比较器:Avonex
Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1, followed by an increase of 7.5 μg each week for 3 weeks, followed by 30 μg intramuscular (IM) injections every week up to Week 96 in Part 1 of the study. Eligible participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks. |
Administered as specified in the treatment arm
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1: Annualized Relapse Rate (ARR) at Week 48
大体时间:Week 48
|
A multiple sclerosis (MS) relapse is defined as the onset of new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings. ARR is calculated as the total number of relapses in each treatment group adjusted for the duration of study treatment in person-years. |
Week 48
|
|
Part 2: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Treatment Discontinuation
大体时间:From Week 96 to Week 196
|
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, or is a medically important event. |
From Week 96 to Week 196
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
第 1 部分:第 24、48 和 96 周脑磁共振成像 (MRI) 扫描中没有新的或新扩大的 T2 高信号病变的参与者百分比
大体时间:第 24、48 和 96 周
|
第 24、48 和 96 周
|
|
|
第 1 部分:第 24、48 和 96 周时大脑中无新 MRI 活动(无钆 [Gd]-增强病灶和新的或新扩大的 T2 高信号病灶)的参与者百分比
大体时间:第 24、48 和 96 周
|
第 24、48 和 96 周
|
|
|
第 1 部分:第 24、48 和 96 周脑部 MRI 扫描中新出现或新扩大的 T2 高信号病灶的数量
大体时间:第 24、48 和 96 周
|
第 24、48 和 96 周
|
|
|
第 1 部分:第 24、48 和 96 周脑 MRI 扫描中 Gd 增强病灶的数量
大体时间:第 24、48 和 96 周
|
第 24、48 和 96 周
|
|
|
第 1 部分:第一次复发的时间
大体时间:直到第 96 周
|
直到第 96 周
|
|
|
第 1 部分:BIIB017 从零时间到给药间隔结束 (AUCtau) 的血浆浓度-时间曲线下面积
大体时间:第 1 周第 1 天给药后 8 小时内;第 4 周第 1 天给药后 8 小时、48 和 120 小时内;第 24 周第 1 天给药后 8 小时内
|
第 1 周第 1 天给药后 8 小时内;第 4 周第 1 天给药后 8 小时、48 和 120 小时内;第 24 周第 1 天给药后 8 小时内
|
|
|
第 1 部分:BIIB017 的稳态最大观察血浆浓度 (Cmax)
大体时间:第 1 周第 1 天给药后 8 小时内;第 4 周第 1 天给药后 8 小时、48 和 120 小时内;第 24 周第 1 天给药后 8 小时内
|
第 1 周第 1 天给药后 8 小时内;第 4 周第 1 天给药后 8 小时、48 和 120 小时内;第 24 周第 1 天给药后 8 小时内
|
|
|
第 1 部分:BIIB017 达到稳态最大观察血浆浓度 (Tmax) 的时间
大体时间:第 1 周第 1 天给药后 8 小时内;第 4 周第 1 天给药后 8 小时、48 和 120 小时内;第 24 周第 1 天给药后 8 小时内
|
第 1 周第 1 天给药后 8 小时内;第 4 周第 1 天给药后 8 小时、48 和 120 小时内;第 24 周第 1 天给药后 8 小时内
|
|
|
第 1 部分:第 48 周和第 96 周未复发的参与者百分比
大体时间:第 48 周和第 96 周
|
第 48 周和第 96 周
|
|
|
第 1 部分:第 24、48、72、96 和 100 周时相对于基线的身高变化
大体时间:基线、第 24、48、72、96 和 100 周
|
基线、第 24、48、72、96 和 100 周
|
|
|
第 1 部分:第 24、48、72、96 和 100 周时体重相对基线的变化
大体时间:基线、第 24、48、72、96 和 100 周
|
基线、第 24、48、72、96 和 100 周
|
|
|
第 1 部分:第 4、8、12、24、36、48、60、72、84、96 和 100 周时血压相对于基线的变化
大体时间:基线,第 4、8、12、24、36、48、60、72、84、96 和 100 周
|
基线,第 4、8、12、24、36、48、60、72、84、96 和 100 周
|
|
|
第 1 部分:第 4、8、12、24、36、48、60、72、84、96 和 100 周时脉率相对于基线的变化
大体时间:基线,第 4、8、12、24、36、48、60、72、84、96 和 100 周
|
基线,第 4、8、12、24、36、48、60、72、84、96 和 100 周
|
|
|
第 1 部分:第 4、8、12、24、36、48、60、72、84、96 和 100 周体温相对于基线的变化
大体时间:基线,第 4、8、12、24、36、48、60、72、84、96 和 100 周
|
基线,第 4、8、12、24、36、48、60、72、84、96 和 100 周
|
|
|
第 1 部分:第 4、8、12、24、36、48、60、72、84、96 和 100 周时呼吸频率相对于基线的变化
大体时间:基线,第 4、8、12、24、36、48、60、72、84、96 和 100 周
|
基线,第 4、8、12、24、36、48、60、72、84、96 和 100 周
|
|
|
第 1 部分:第 48、96 和 100 周时 12 导联心电图 (ECG) 参数相对于基线的变化
大体时间:基线(给药前)、第 48、96 和 100 周
|
基线(给药前)、第 48、96 和 100 周
|
|
|
第 2 部分:第 120、144、168、192 和 196 周时相对于基线的身高变化
大体时间:基线(第 96 周)、第 120、144、168、192 和 196 周
|
基线(第 96 周)、第 120、144、168、192 和 196 周
|
|
|
第 2 部分:第 120、144、168、192 和 196 周时体重相对基线的变化
大体时间:基线(第 96 周)、第 120、144、168、192 和 196 周
|
基线(第 96 周)、第 120、144、168、192 和 196 周
|
|
|
第 2 部分:第 120,144,168、192 和 196 周时血压相对于基线的变化
大体时间:基线(第 96 周)、第 120、144、168、192 和 196 周
|
基线(第 96 周)、第 120、144、168、192 和 196 周
|
|
|
第 2 部分:第 120、144、168、192 和 196 周时脉率相对于基线的变化
大体时间:基线(第 96 周)、第 120、144、168、192 和 196 周
|
基线(第 96 周)、第 120、144、168、192 和 196 周
|
|
|
第 2 部分:第 120、144、168、192 和 196 周体温相对于基线的变化
大体时间:基线(第 96 周)、第 120、144、168、192 和 196 周
|
基线(第 96 周)、第 120、144、168、192 和 196 周
|
|
|
第 2 部分:第 120、144、168、192 和 196 周时呼吸频率相对于基线的变化
大体时间:基线(第 96 周)、第 120、144、168、192 和 196 周
|
基线(第 96 周)、第 120、144、168、192 和 196 周
|
|
|
第 2 部分:第 144、192 和 196 周时 12 导联心电图参数相对于基线的变化
大体时间:基线(第 96 周)、第 144、192 和 196 周
|
基线(第 96 周)、第 144、192 和 196 周
|
|
|
Part 1: ARR at Week 96
大体时间:Week 96
|
An MS relapse is defined as the onset of new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings. ARR is calculated as the total number of relapses in each treatment group adjusted for the duration of study treatment in person-years. |
Week 96
|
|
Part 1: Change from Baseline in Cognition at Weeks 24, 48, 72, and 96 as Measured by the Symbol Digit Modality Test (SDMT)
大体时间:Baseline, Weeks 24, 48, 72, and 96
|
The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0 (worst) to 110 (best) in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. Higher scores indicate better performance. |
Baseline, Weeks 24, 48, 72, and 96
|
|
Part 1: Change from Baseline in the Expanded Disability Status Scale (EDSS) Score at Weeks 48 and 96
大体时间:Baseline, Weeks 48, and 96
|
EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in MS. Scores range from 0.0 (normal) to 10.0 (death due to MS). |
Baseline, Weeks 48, and 96
|
|
Part 1: Change from Baseline in the Quality of Life as Measured by the Pediatric Quality of Life Inventory (PedsQL) at Weeks 24, 48, 72 and 96
大体时间:Baseline, Weeks 24, 48, 72 and 96
|
The PedsQL consists of 23 items in four generic score scales: physical functioning, emotional functioning, social functioning, and school functioning that measures health related quality of life. The questionnaire asks how much of a problem each item has been during the past month. Each item is answered on a scale of 0 (never) to 4 (almost always) then the scores are transformed to a 0 to 100 scale, so that higher scores indicate better heath related quality of life. |
Baseline, Weeks 24, 48, 72 and 96
|
|
Part 1: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Study Treatment Discontinuation
大体时间:Up to Week 100
|
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, or is a medically important event. |
Up to Week 100
|
|
Part 1: Change from Baseline in Tanner Score at Weeks 24, 48, 72, 96, and 100
大体时间:Baseline, Weeks 24, 48, 72, 96, and 100
|
Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected for all male participants with bone age less than (<) 16 years and for female participants who are pre-menarche and have a bone age < 16 years and will be stopped once the participant's bone age reaches greater than or equal to (>=) 16 years or (once the participant is post-menarche. Tanner Score can be omitted if required by country-specific regulations and/or local ethics committees. |
Baseline, Weeks 24, 48, 72, 96, and 100
|
|
Part 1: Number of Participants With Binding and Neutralizing Antibodies to Interferon Beta Type 1a (IFN β-1a) [All Participants]
大体时间:Up to Week 96
|
Presence of IFN β-1a antibodies in human serum will be determined using enzyme-linked immunosorbent assay (ELISA) followed by further characterization and titration of positive samples in a cell-based neutralizing antibody assay. |
Up to Week 96
|
|
Part 1: Number of Participants With Binding Antibodies to Peginterferon (PEG) [BIIB017-Treated Participants]
大体时间:Up to Week 96
|
Anti-PEG binding antibodies in human serum will be determined using an ELISA. |
Up to Week 96
|
|
Part 1: Change from Baseline in Depression as Assessed by Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) at Weeks 12, 24, 36, 48, 60, 72, 84, 96, and 100
大体时间:Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, and 100
|
MINI-KID is a short (approximately 15 minute) structured diagnostic interview used to assess the presence of 20 diagnostic and statistical manual of mental disorders, 4th Edition (DSM-IV) child and adolescent psychiatric disorders as well as the risk of suicide. The MINI-Kid frames questions in language that is easy for children and adolescents. It consists of 137 questions across 24 modules. |
Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, and 100
|
|
Part 1: Percentage of Participants with Changes Over Time in Clinical Laboratory Values
大体时间:Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100
|
Clinical laboratory tests include: hematology, chemistry (including liver, renal and thyroid function), and coagulation tests. |
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100
|
|
Part 2: ARR at Weeks 144 and 192
大体时间:Weeks 144 and 192
|
An MS relapse is defined as the onset of new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings. ARR is calculated as the total number of relapses in each treatment group adjusted for the duration of study treatment in person-years. |
Weeks 144 and 192
|
|
Part 2: Change from Baseline in EDSS Score at Weeks 120, 144, 168, 192, and 196
大体时间:Baseline (Week 96), Weeks 120, 144, 168, 192, and 196
|
EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in MS. Scores range from 0.0 (normal) to 10.0 (death due to MS). |
Baseline (Week 96), Weeks 120, 144, 168, 192, and 196
|
|
Part 2: Change from Baseline in Tanner Score at Weeks 120, 144, 168, 192, and 196
大体时间:Baseline (Week 96), Weeks 120, 144, 168, 192, and 196
|
Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected for all male participants with bone age < 16 years and for female participants who are pre-menarche and have a bone age <16 years and will be stopped once the participant's bone age reaches >= 16 years or (once the participant is post-menarche. Tanner Score can be omitted if required by country-specific regulations and/or local ethics committees. |
Baseline (Week 96), Weeks 120, 144, 168, 192, and 196
|
|
Part 2: Number of Participants With Binding and Neutralizing Antibodies to IFN β-1a (All Participants)
大体时间:Up to Week 192
|
Presence of IFN β-1a antibodies in human serum will be determined using ELISA followed by further characterization and titration of positive samples in a cell-based neutralizing antibody assay. |
Up to Week 192
|
|
Part 2: Number of Participants With Binding Antibodies to PEG (BIIB017-Treated Participants)
大体时间:Up to Week 192
|
Anti-PEG binding antibodies in human serum will be determined using an ELISA. |
Up to Week 192
|
|
Part 2: Change from Baseline in Depression as Assessed by Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) at Weeks 108, 120, 132, 144,156, 168, 180, 192, and 196
大体时间:Baseline (Week 96), Weeks 108, 120, 132, 144,156, 168, 180, 192, and 196
|
MINI-KID is a structured diagnostic interview instrument for psychiatric evaluation and outcome tracking. All questions are answered Yes or No. |
Baseline (Week 96), Weeks 108, 120, 132, 144,156, 168, 180, 192, and 196
|
|
Part 2: Percentage of Participants with Changes Over Time in Clinical Laboratory Values
大体时间:Baseline (Week 96), Weeks 108, 120, 132, 144, 156, 168, 180, 192, and 196
|
Clinical laboratory tests include: hematology, chemistry (including liver, renal and thyroid function), and coagulation tests. |
Baseline (Week 96), Weeks 108, 120, 132, 144, 156, 168, 180, 192, and 196
|
合作者和调查者
赞助
调查人员
- 研究主任:Medical Director、Biogen
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 105MS306
- 2018 (美国 NIH 拨款/合同)
- 2018-003008-38 (EudraCT编号)
- 2023-505624-56 (其他标识符:EU CTIS)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.